Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.Pipeline progress included the approval ...
If you take dietary supplements intending to improve your overall health, you aren't alone. Close to 75% of all US adults say ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...